Shares of ResMed Inc. RMD rose 1.12% to $239.78 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 1.00% to 5,996.66 and the ...

Shares of ResMed Inc. RMD rallied 1.61% to $237.13 Thursday, on what proved to be an all-around poor trading session for the ...

The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...

Dave hadn't felt well before but had been told it was down to smoking, shift work, allergies, poor diet - and even his pillow ...

Fintel reports that on January 10, 2025, Piper Sandler initiated coverage of ResMed (NYSE:RMD) with a Neutral recommendation.

Adam Maeder, an analyst from Piper Sandler, has initiated a new Hold rating on Resmed (RMD).Stay Ahead of the Market:Discover outperforming ...

OSA impacts about 936 million people worldwide and occurs when the throat muscles relax and block the airway with a common ...

The global continuous positive airway pressure (CPAP) market is projected to reach a value of USD 900 million by 2033, ...

ResMed launches AirSense 11, to advance digital health in sleep apnoea for Indians: Our Bureau, Bengaluru Monday, January 6, 2025, 17:30 Hrs [IST] ResMed, the world’s leading he ...